PSMA-RADS to improve evaluation and management of prostate cancer.

IF 2.3 3区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Abdominal Radiology Pub Date : 2024-12-20 DOI:10.1007/s00261-024-04738-2

Niloufar Rafiei Alavi, Maryam Rahmani, Arti Gupta, Vahid Yaghmai

{"title":"PSMA-RADS to improve evaluation and management of prostate cancer.","authors":"Niloufar Rafiei Alavi, Maryam Rahmani, Arti Gupta, Vahid Yaghmai","doi":"10.1007/s00261-024-04738-2","DOIUrl":null,"url":null,"abstract":"Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) / computed tomography (CT) has become essential in managing prostate cancer, offering superior diagnostic accuracy. The introduction of the U.S. Food and Drug Administration (FDA)-approved theranostic agent (177Lutetium-PSMA-617) has further enhanced the significance of PSMA PET/CT imaging. Despite its benefits, PSMA-PET/CT is not without challenges, as PSMA expression is not exclusive to prostate cancer cells. Therefore, standardized interpretation criteria are necessary for consistent and reliable communication among physicians. The PSMA- reporting and data system (RADS) provides a structured approach for assessing PSMA-PET/CT scans. Updated in 2023, PSMA-RADS 2.0 addresses previous limitations and introduces a new category, PSMA-RADS 5T, for treated metastases. This system categorizes lesions based on their likelihood of prostate cancer involvement, improving longitudinal monitoring and guiding management strategies. By familiarizing radiologists with PSMA-RADS through case-based reviews, this primer aims to enhance diagnostic accuracy and treatment planning for patients with prostate cancer.","PeriodicalId":7126,"journal":{"name":"Abdominal Radiology","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Abdominal Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00261-024-04738-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) / computed tomography (CT) has become essential in managing prostate cancer, offering superior diagnostic accuracy. The introduction of the U.S. Food and Drug Administration (FDA)-approved theranostic agent (¹⁷⁷Lutetium-PSMA-617) has further enhanced the significance of PSMA PET/CT imaging. Despite its benefits, PSMA-PET/CT is not without challenges, as PSMA expression is not exclusive to prostate cancer cells. Therefore, standardized interpretation criteria are necessary for consistent and reliable communication among physicians. The PSMA- reporting and data system (RADS) provides a structured approach for assessing PSMA-PET/CT scans. Updated in 2023, PSMA-RADS 2.0 addresses previous limitations and introduces a new category, PSMA-RADS 5T, for treated metastases. This system categorizes lesions based on their likelihood of prostate cancer involvement, improving longitudinal monitoring and guiding management strategies. By familiarizing radiologists with PSMA-RADS through case-based reviews, this primer aims to enhance diagnostic accuracy and treatment planning for patients with prostate cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

PSMA-RADS 改善前列腺癌的评估和管理。

前列腺特异性膜抗原（PSMA）正电子发射断层扫描(PET) /计算机断层扫描（CT）已成为治疗前列腺癌必不可少的，提供卓越的诊断准确性。美国食品和药物管理局（FDA）批准的治疗剂（177Lutetium-PSMA-617）的引入进一步增强了PSMA PET/CT成像的意义。尽管有好处，PSMA- pet /CT也不是没有挑战，因为PSMA的表达并不仅限于前列腺癌细胞。因此，标准化的解释标准对于医生之间一致可靠的沟通是必要的。PSMA报告和数据系统（RADS）为评估PSMA- pet /CT扫描提供了一种结构化方法。PSMA-RADS 2.0于2023年更新，解决了以前的限制，并引入了治疗转移的新类别PSMA-RADS 5T。该系统根据病变累及前列腺癌的可能性对病变进行分类，改善纵向监测并指导管理策略。通过基于病例的回顾，使放射科医生熟悉PSMA-RADS，本引物旨在提高前列腺癌患者的诊断准确性和治疗计划。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Abdominal Radiology Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

5.20

自引率

8.30%

发文量

334

期刊介绍： Abdominal Radiology seeks to meet the professional needs of the abdominal radiologist by publishing clinically pertinent original, review and practice related articles on the gastrointestinal and genitourinary tracts and abdominal interventional and radiologic procedures. Case reports are generally not accepted unless they are the first report of a new disease or condition, or part of a special solicited section. Reasons to Publish Your Article in Abdominal Radiology: · Official journal of the Society of Abdominal Radiology (SAR) · Published in Cooperation with: European Society of Gastrointestinal and Abdominal Radiology (ESGAR) European Society of Urogenital Radiology (ESUR) Asian Society of Abdominal Radiology (ASAR) · Efficient handling and Expeditious review · Author feedback is provided in a mentoring style · Global readership · Readers can earn CME credits